Clinicopathological analysis of borderline ovarian tumours and risk factors related to recurrence: experience of single institution

Sözen, Hamdullah; Vatansever, Doğan; Topuz, Samet; Iyibozkurt, Cem; Kandemir, Hülya; Yalçın, İbrahim; Önder, Semen; Yavuz, Ekrem; Salihoğlu, Yavuz

doi:10.1080/01443615.2018.1499076

Cited by 21 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most BOTs can be diagnosed in the early stage, but it is reported that the recurrence rate ranges from 5 to 20% [5], and the recurrence and mortality rates have gradually increased. While the BOT onset age has dropped in recent years, with improvements in the quality of life and the implementation of the two-child policy in China, more and more patients wish to retain their reproductive function.…”

Section: Introductionmentioning

confidence: 99%

Recurrence characteristics and clinicopathological results of borderline ovarian tumors

Niu

Tian

et al. 2021

BMC Women's Health

View full text Add to dashboard Cite

Background This study aimed to investigate the clinical and pathological characteristics, and the recurrence and prognostic factors of borderline ovarian tumors (BOTs). Methods The data of 286 patients admitted to hospital and followed up for more than ten months were analyzed retrospectively to study the clinicopathological characteristics and related factors of recurrence. Results The median age of the patients was 42.06 ± 14.97 years, and the duration of the follow-up ranged from 10–109 months. During the follow-up period, 40 patients had a recurrence. Of these patients, 36 were ≤ 40 years, and patients with premenopausal recurrence accounted for 20.5% (36/176). In patients undergoing conservative treatment or radical operations, the recurrence rates were 21.3% and 1.8%, respectively, and they were 13.4% (36/268) in patients at Federation International of Gynecology and Obstetrics (FIGO) stage I, and 22.2% (4/18) in patients at an advanced stage. Postoperative pathology revealed that 40 patients had micropapillary tumors, among whom ten patients (25%) had a recurrence, and 19 patients had complications with interstitial infiltration. Of these 19 patients, six had a recurrence (31.5%). Another 22 patients had complications with calcified sand bodies; among these, eight patients (36.4%) had a recurrence. All the differences were statistically significant (P < 0.05). There were four cancer-related deaths during the follow-up period. Late FIGO stage, conservative operation, and a high level of carbohydrate antigen 125 (CA125) were independent risk factors for the recurrence of BOTs. Conclusion BOTs usually occur in women under 40 years, have an occult onset, and half of the patients have no obvious clinical manifestations. Serum CA125 level can be used as a tumor marker to detect BOTs and the risk of its recurrence. Operation mode and FIGO stage are important independent factors for the recurrence of BOTs.

show abstract

Section: Introductionmentioning

confidence: 99%

Recurrence characteristics and clinicopathological results of borderline ovarian tumors

Niu

Tian

et al. 2021

BMC Women's Health

View full text Add to dashboard Cite

show abstract

“…However, not all cases diagnosed as invasive ovarian malignancy after initial treatment for a BOT can be easily classified as recurrent disease or malignant transformation arising from the BOT. An advanced FIGO stage has been found to be the most prominent prognostic factor, with elevated preoperative serum CA-125 and the presence of micropapillary features as risk factors for an advanced stage at presentation (5,7). In our case, the patient's advanced age and elevated preoperative CA-125 level and pulmonary involvement of the BOT predicated a high likelihood of malignant transformation.…”

Section: Discussionmentioning

confidence: 58%

“…A systematic review ( 6 ) showed that 37% of recurrences are diagnosed during the first 2 years, 31% in years 2–5, and 32% more than 5 years after diagnosis, including 10% after more than 10 years. In different retrospective cohort studies, recurrent or persistent BOTs and malignant transformation following initial treatment were noted in 4 ~20% of patients, with a median progression-free survival (PFS) time of 14 months (1 ~36 months) ( 5 , 7 ). Thus, close long-term follow-ups are essential for patients.…”

Section: Discussionmentioning

confidence: 99%

Malignant Transformation of a Borderline Ovarian Tumor With Pulmonary and Pleural Metastases After Years of Latency: A Case Report and Literature Review

Miao

Liang

et al. 2020

Front. Med.

View full text Add to dashboard Cite

Borderline ovarian tumor (BOT) refers to a distinct tumor of the ovary of epithelial origin and typically has a favorable prognosis. However, these tumors are not exempt from risks of recurrence and malignant transformation, which can arise from the remaining ovarian tissue, peritoneal implants, or distant localization. Here, we report a case of a mucinous BOT with multiple pulmonary cystic nodules without evidence of pulmonary metastasis even after two fine needle biopsies. Staging surgery was performed, and no evidence of peritoneal implants or invasion to adjacent organs found. At the end of the 7-year monitored follow-up after surgery, the pulmonary lesions were found to be increased in size. The transbronchial lung biopsy and pleural biopsy confirmed transformation into malignant mucinous adenocarcinoma with pleural metastasis. In the current case, we observed potential pulmonary metastasis of the BOT with malignant transformation and a latency as long as 7 years, which reminds us that multiple pulmonary cystic changes in patients with BOTs should be screened carefully to evaluate the pulmonary involvement of BOTs and potentially false-negative results after fine needle biopsy. Thus, a thorough checkup for complete staging of the disease and a close long-term follow-up to monitor potential recurrence and malignant transformation are advised.

show abstract

“…We speculate that the reason colorectal, breast, pancreatic, and genital system-related tumors occupy a large proportion in young patients is that the number of colorectal cancer or breast cancer patients is large [4], and the liver is the preferred metastatic organ of colorectal cancer [10] and pancreatic cancer [9]. Furthermore, pancreatic cancer has a very high rate of hepatic metastasis [9], and the median age of breast cancer [25] and genital system-related tumors is relatively low (less than 65 years) [26,27].…”

Section: Discussionmentioning

confidence: 99%

Distribution of primary site of hepatic metastases and prognosis of hepatic metastases at different primary sites

Zhou

Zhao

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Most of the time, the primary tumor of hepatic metastases is easy to find. However, sometimes this is a confusing question. The present study aimed to explore the distribution of primary sites of hepatic metastases and the prognosis of hepatic metastases at different primary sites. Methods Data on patients with hepatic metastases were obtained from the surveillance, epidemiology, and end results (SEER) database between 2010 and 2016. Descriptive statistics was used to analyze the distribution of primary sites, life table to calculate survival rate, Kaplan-Meier method to plot survival curves, and Cox univariate regression and multivariate regression analysis to assess prognostic factors. Results The median age of 151,821 patients was 67 years; 58.7% of the primary sites were derived from the digestive system, followed by the respiratory system (25.6%) and other sites (15.8%). Ten leading primary sites were lung (25.4%), colorectum (24.1%), pancreas (19.8%), stomach (4.5%), breast (4.1%), gallbladder and biliary system (3%), esophagus (2.7%), kidney and renal pelvis (2.1%), ovary (1.8%) and primary sites unknown (2%). The overall survival probability of patients with hepatic metastases at 6 months, 1 year, and 3 years was 44.5%, 28.7%, and 9.9%, respectively, with a median survival of 4 months. The prognosis of hepatic metastases from lymphoma (Hodgkin and non-Hodgkin), the small intestine, breast, and colorectum was relatively better, and that from primary sites unknown, urinary system (bladder, urethra), lung, and pancreas was quite poor. Conclusion The distribution of primary sites of hepatic metastases was different under different grouping conditions, but the lung, colorectum and pancreas were the top three sources. The prognosis of hepatic metastases from different primary sites varied greatly.

show abstract

Clinicopathological analysis of borderline ovarian tumours and risk factors related to recurrence: experience of single institution

Cited by 21 publications

References 18 publications

Recurrence characteristics and clinicopathological results of borderline ovarian tumors

Recurrence characteristics and clinicopathological results of borderline ovarian tumors

Malignant Transformation of a Borderline Ovarian Tumor With Pulmonary and Pleural Metastases After Years of Latency: A Case Report and Literature Review

Distribution of primary site of hepatic metastases and prognosis of hepatic metastases at different primary sites

Contact Info

Product

Resources

About